{
  "abstract": "Purpose: 177Lu-PSMA is currently approved for metastatic castration-resistant prostate cancer (mCRPC). However, only a subset of eligible patients derives a meaningful clinical benefit from treatment. To date, there is a lack of validated biomarkers that could help find the best candidates for this radioligand therapy (RLT).\n\nMethods: 142 patients undergoing 177Lu-PSMA therapy were enrolled in a biological observational prospective study, with blood samples collected at baseline for analysis. Clinical characteristics and routinely available laboratory biomarkers – including hemoglobin, alkaline phosphatase, prostate-specific antigen (PSA), and carcinoembryonic antigen (CEA) – were evaluated by uni- and multivariable Cox regression analyses for their association with progression-free survival (PFS) and overall survival (OS).\n\nResults: At a median follow-up of 44.0 months, median PFS and OS were 7.0 and 16.8 months, respectively. Elevated baseline CEA was independently associated with shorter PFS (p = 0.026) and OS (p = 0.003). Moreover, combining CEA with PSA improved prognostic discrimination compared with PSA alone.\n\nConclusion: Baseline CEA was independently associated with shorter PFS and OS, supporting its role as a promising prognostic biomarker for patients with mCRPC undergoing 177Lu-PSMA therapy. Further studies are warranted to validate its prognostic value and determine whether it also has predictive utility.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy",
    "Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy",
    "Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy",
    "Department of Experimental Medicine, University of Salento, Lecce, Italy"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Emilio Francesco Giunta",
      "orcid": "0000-0002-5383-4469"
    },
    {
      "affs": [
        1
      ],
      "name": "Irene Marini"
    },
    {
      "affs": [
        1
      ],
      "name": "Ilaria Grassi"
    },
    {
      "affs": [
        1
      ],
      "name": "Silvia Nicolini"
    },
    {
      "affs": [
        2
      ],
      "name": "Flavia Foca"
    },
    {
      "affs": [
        1
      ],
      "name": "Monica Celli"
    },
    {
      "affs": [
        1
      ],
      "name": "Paola Caroli"
    },
    {
      "affs": [
        1
      ],
      "name": "Anna Sarnelli"
    },
    {
      "affs": [
        0
      ],
      "name": "Nicole Brighi"
    },
    {
      "affs": [
        0
      ],
      "name": "Giuseppe Schepisi"
    },
    {
      "affs": [
        2
      ],
      "name": "Manuela Monti"
    },
    {
      "affs": [
        3
      ],
      "name": "Ugo De Giorgi"
    },
    {
      "affs": [
        0
      ],
      "name": "Cristian Lolli"
    },
    {
      "affs": [
        1
      ],
      "name": "Maddalena Sansovini"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8hmkdsf60wy2z.bib",
  "cited_by": 0,
  "doi": "10.1007/s00259-026-08173-x",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13727948/",
  "id": "8hmkdsf60wy2z",
  "issns": [
    "1619-7070",
    "1619-7089"
  ],
  "landing_url": "https://doi.org/10.1007/s00259-026-08173-x",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2741|Radiopharmaceutical Chemistry and Applications"
    ]
  ],
  "openalex": "W7212180235",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s00259-026-08173-x.pdf",
  "pmcid": "PMC13727948",
  "pmid": "42722919",
  "published": "2026-09-11",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8hmkdsf60wy2z.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T12:23:43Z",
      "native_id": "PMC13727948",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s00259-026-08173-x"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2741|Radiopharmaceutical Chemistry and Applications",
      "subfield": "imaging"
    }
  ],
  "title": "Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy",
  "title_text": "Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:21:02Z",
  "url": "https://research.draconitic.com/paper/8hmkdsf60wy2z",
  "venue": "European Journal of Nuclear Medicine and Molecular Imaging",
  "versions": []
}